Please enable JavaScript.
Coggle requires JavaScript to display documents.
COVID - 19
(Coronavirus) - Coggle Diagram
COVID - 19
(Coronavirus)
-
Since the first case was reported in 2019 to the World Health Organization (WHO) in Wuhan, China, the virus has claimed the lives of more than 2,200 people and confirmed cases exceed 75,740.
-
The first cases occurred between 12 and 29 December 2019, according to Wuhan health authorities.
-
The World Health Organization (WHO) raised the coronavirus risk alert from "high" to "very high" on February 28, due to the increase in infections and affected countries. By that date, the disease had reached more than 50 nations.
-
The World Health Organization (WHO) considered on March 11 that the spread of COVID-19 can be characterized as a pandemic, noting that the number of cases outside China increased 13-fold and the number of affected countries tripled in just two weeks.
-
Human coronaviruses are common and are typically associated with mild illnesses, similar to the common cold.
-
On January 23, Wuhan was quarantined in an attempt to limit the spread of the virus. The isolation was extended to 13 other cities, affecting 36 million people.
-
COVID-19 has already elicited memories of the Sars outbreak in Hong Kong, bringing feelings of dread and sorrow. Those with experience of the HIV/AIDS epidemic have spoken about the COVID-19 pandemic evoking feelings of “unresolved grief and anger”.
In the future we might be driven by a similar fear, for example, and start stockpiling food or toilet paper at the first sign of a new disease being discovered, even if the situation doesn’t warrant such action.
This crisis has already thrown up acts of solidarity and ideas about how we can use it to make positive changes. These can provide an alternative narrative for our communities, alternative memories, and a source of strength to face future crises.
-
Coronaviruses are a large group of viruses common among animals. They can affect people, usually with moderate illness.
-
The results of the first phase of clinical trials of a vaccine candidate in China demonstrate that it is safe, well tolerated and capable of generating an immune response against COVID-19 in humans.
-
